Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas GSK is the largest ...
Fierce Pharma

CDMO Bora locks in 5-year, $250M production agreement with GSK

With a productive working relationship between the two companies already well established, Bora Pharmaceuticals is renewing a $250 million global manufacturing agreement with British drugmaker GSK. | ...
PharmExec

Pharma Manufacturing Roundup: AbbVie Invests $380 Million to Expand API Manufacturing, Bora Pharmaceuticals and GSK Enters Five Year Manufacturing Agreement

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.
FiercePharma

Bora's expansion tear continues as CDMO takes up stake in Tanvex, gains manufacturing capabilities

Bora Pharmaceuticals extended its expansion tear by taking a 30.5% stake in fellow Taiwanese drugmaker Tanvex BioPharma, boosting the CDMO’s biomanufacturing capabilities. The deal, which is expected ...
Business Wire

Bora Pharmaceuticals Announces Multi-Year Expansion for Midwest Manufacturing Site, as Upsher-Smith Entity Split is Finalized

MAPLE GROVE, Minn.--(BUSINESS WIRE)--Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, has announced plans for significant ...